Indications & Goals - Weighing the Options
- Primary Goal: Achieve clinically significant weight loss (≥ 5-10% of initial body weight) to mitigate obesity-related health risks.
- Indications (Indian/Asian Adults):
- BMI ≥ 25 kg/m² (Obesity).
- BMI ≥ 23 kg/m² (Overweight) with ≥ 1 significant comorbidity (e.g., T2DM, hypertension, dyslipidemia, OSA, CVD).
- Pre-requisite: Pharmacotherapy is considered after failure of comprehensive lifestyle interventions (diet, physical activity, behavioral changes) for at least 3-6 months.
- Key Considerations: Patient motivation, realistic goals, risk-benefit assessment for individual agents.
⭐ Pharmacotherapy for obesity is an adjunct to, not a substitute for, sustained lifestyle modifications.
Central Mechanisms - Brainy Weight Busters
Central agents modulate neurotransmitters or receptors in the hypothalamus (appetite regulation center) or reward pathways to reduce appetite or increase satiety.
| Agent | MOA Highlights | Avg. Wt. Loss | Key AEs/CIs (⚠️) |
|---|---|---|---|
| Phentermine/Topiramate | NE release (↓appetite); GABA-R modulation (↑satiety) | ~9-11% | Tachycardia, paresthesia. ⚠️ Glaucoma, hyperthyroidism, MAOI use. Teratogenic. |
| Naltrexone/Bupropion | µ-opioid antagonist + DA/NE reuptake inhibitor (↓cravings, ↑POMC) | ~5-9% | Nausea, headache. ⚠️ Seizures, uncontrolled HTN, opioid use. Black Box: Suicidality. |
| Liraglutide (Saxenda) | GLP-1 RA (↑satiety, ↓gastric emptying) 📌 '-glutide' | ~5-8% (3mg) | GI (nausea, vomiting), pancreatitis. ⚠️ Hx MTC/MEN2. |
| Semaglutide (Wegovy) | GLP-1 RA (↑satiety, ↓gastric emptying) 📌 '-glutide' | ~15-17% (2.4mg) | GI (nausea, vomiting), pancreatitis. ⚠️ Hx MTC/MEN2. |
⭐ > Naltrexone/Bupropion synergistically targets both hypothalamic melanocortin pathways (reducing hunger) and mesolimbic reward pathways (reducing cravings).
Peripheral Mechanisms - Gut Feeling Fighters
- Orlistat (Xenical, Alli)
- MOA: Reversible inhibitor of pancreatic & gastric lipases.
- Prevents hydrolysis of dietary triglycerides.
- ↓ dietary fat absorption by ~30%.
- Dose: 120 mg TID (with main meals containing fat).
- Side Effects:
- GI: Steatorrhea (oily spotting, flatus with discharge, fecal urgency). 📌 'Oily'stat.
- ↓ absorption of fat-soluble vitamins (A, D, E, K) - supplement 2 hours apart.
- Interactions: Warfarin (↑ INR via ↓ Vit K), Cyclosporine (↓ levels - administer 2-3 hours apart).
⭐ Orlistat is a peripherally acting lipase inhibitor; it does not affect appetite or satiety centers in the brain.
- MOA: Reversible inhibitor of pancreatic & gastric lipases.
Drug Comparison & Safety - Safe Slimming Strategies
Drug Comparison: Key Features
| Drug | MOA | Efficacy (Avg. WL) | Key AEs | Key CIs |
|---|---|---|---|---|
| Orlistat | Inhibits pancreatic/gastric lipase; ↓fat absorption | ~3-5% | GI: Steatorrhea, fecal urgency, oily spotting | Chronic malabsorption, cholestasis |
| Liraglutide | GLP-1 RA: ↑satiety, ↓appetite, delays gastric emptying | ~5-8% | N/V/D, pancreatitis risk | Hx Medullary Thyroid Ca (MTC)/MEN2 |
| Semaglutide | GLP-1 RA: Potent; ↑satiety, ↓appetite, delays gastric emptying | ~10-15% | N/V/D (often dose-dep.), pancreatitis risk | Hx MTC/MEN2 |
| Naltrexone/Bupropion | Naltrexone (opioid antag) + Bupropion (NDRI): Modulates appetite | ~5% | Nausea, headache, insomnia, ↑BP/HR | Seizures, uncontrolled HTN, MAOI use, chronic opioid use |
* Goal: Clinically significant weight loss (≥**5%**).
* Discontinue if <**5%** weight loss at **3 months** (12 weeks).
* ⚠️ All generally contraindicated in pregnancy, breastfeeding.
⭐ GLP-1 RAs (Liraglutide, Semaglutide) offer cardiovascular benefits in T2DM patients, a crucial advantage beyond weight loss.
Simplified Drug Selection Flow
High‑Yield Points - ⚡ Biggest Takeaways
- Orlistat: Lipase inhibitor; causes steatorrhea, fat-soluble vitamin deficiency. Monitor INR with warfarin.
- GLP-1 agonists (Liraglutide, Semaglutide): Suppress appetite, delay gastric emptying; nausea common. Thyroid C-cell tumor risk.
- Naltrexone/Bupropion: Opioid antagonist + DA/NE reuptake inhibitor. BBW: Suicidality.
- Phentermine/Topiramate: Sympathomimetic + antiepileptic. Short-term use; CV risks, teratogenic.
- Setmelanotide: MC4R agonist for rare genetic obesities (POMC, PCSK1, LEPR).
- Crucial: Note contraindications (e.g., pregnancy, MAOIs) & key AEs for each drug class.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
